Giorgi-Coll Susan, Blunt-Foley Holly, Hutchinson Peter J, Carpenter Keri L H
Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Box 167, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Box 65, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
Anal Bioanal Chem. 2017 Aug;409(21):5031-5042. doi: 10.1007/s00216-017-0447-y. Epub 2017 Jun 29.
Cerebral microdialysis is a sampling technique which offers much potential for understanding inflammatory pathophysiology following traumatic brain injury (TBI). At present, the recovery of cytokines via microdialysis in clinical studies is not straightforward primarily due to their size, steric properties and low concentrations. Heparin and heparin-coated microspheres have previously shown promise as cytokine-binding agents for enhanced microdialysis sampling in animal models (Duo and Stenken in Anal Bioanal Chem 399(2):773-82, 2011; Anal Bioanal Chem 399(2):783-93, 2011). However, there are several factors limiting application for microdialysis in patients. The aim of this study was to produce heparin-coated gold nanoparticles as cytokine capture agents for enhanced microdialysis sampling, potentially applicable to a clinical setting. Gold nanoparticles (AuNP) were chemically conjugated to heparin via a bifunctional polyethylene glycol (PEG) linker. The heparin-AuNP (AuNP-Hep) were characterised, demonstrating the successful addition of heparin to the gold surface. The performance of the AuNP-Hep during in vitro testing was compared both to current methodology (Helmy et al. in J Neurotrauma 26(4):549-61, 2009) and to the heparin-coated microspheres developed by Duo and Stenken (Anal Bioanal Chem 399(2):773-82, 2011; Anal Bioanal Chem 399(2):783-93, 2011). The AuNP-Hep yielded a higher recovery of cytokines compared to current methodology and heparin-coated microspheres, during in vitro testing designed to mimic the human environment and the intensive care unit. In this study, AuNP-Hep were developed for enhanced microdialysis sampling of cytokines, potentially applicable in a clinical setting. Based on the success of the AuNP-Hep in vitro, the proposed method offers an alternative to the use of current protocols that rely on a blood product (albumin) for microdialysis sampling of cytokines in patients.
脑微透析是一种采样技术,在理解创伤性脑损伤(TBI)后的炎症病理生理学方面具有很大潜力。目前,在临床研究中通过微透析回收细胞因子并非易事,主要是由于它们的大小、空间特性和低浓度。肝素和肝素包被的微球先前已显示出有望作为细胞因子结合剂,用于在动物模型中增强微透析采样(Duo和Stenken,《分析与生物分析化学》399(2):773 - 82,2011年;《分析与生物分析化学》399(2):783 - 93,2011年)。然而,有几个因素限制了微透析在患者中的应用。本研究的目的是制备肝素包被的金纳米颗粒作为细胞因子捕获剂,用于增强微透析采样,可能适用于临床环境。金纳米颗粒(AuNP)通过双功能聚乙二醇(PEG)连接子与肝素化学偶联。对肝素 - 金纳米颗粒(AuNP - Hep)进行了表征,证明肝素成功添加到了金表面。在体外测试中,将AuNP - Hep的性能与当前方法(Helmy等人,《神经创伤杂志》26(4):549 - 61,2009年)以及Duo和Stenken开发的肝素包被微球(《分析与生物分析化学》399(2):773 - 82,2011年;《分析与生物分析化学》399(2):783 - 93,2011年)进行了比较。在旨在模拟人体环境和重症监护病房的体外测试中,与当前方法和肝素包被微球相比,AuNP - Hep产生了更高的细胞因子回收率。在本研究中,开发了AuNP - Hep用于增强细胞因子的微透析采样,可能适用于临床环境。基于AuNP - Hep在体外的成功,所提出的方法为目前依赖血液制品(白蛋白)进行患者细胞因子微透析采样的方案提供了一种替代方法。